aRCC: 1L Treatment Options and Patient Management

 

ASCO Genitourinary Cancers Symposium
S

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up: Efficacy and Safety of Nivo+Ipi vs. Sunitinib for 1L Treatment of Advanced sRCC

By ASCO Genitourinary Cancers Symposium FEATURING Scott Tykodi
By ASCO Genitourinary Cancers Symposium FEATURING Scott Tykodi
173 views
March 14, 2022
0 Comments
Login to view comments. Click here to Login
aRCC: 1L Treatment Options and Patient Management
12:14
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

Feat. S. Tykodi
08:40
Thomas Hutson

Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …

16:00
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

Feat. M. Dean
09:23
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

Feat. R. McKay
16:34
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

Feat. N. Haas
06:04
ASCO 2022 Conference Coverage

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA…

Feat. L. Albiges
47:32
Moffitt Cancer Center

Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy i…

Feat. J. Gao
13:28
Total Health

2022 ASCO Renal Cell Carcinoma Updates

Feat. M. Bupathi
12:53
O'Neal Comprehensive Cancer Center at UAB

Dual Immunotherapy in RCC

Feat. A. Basu
20:47
ecancer

ESMO 2022 on the Latest in mRCC

Feat. J. Puente, B. Escudier, V. Grünwald, S. Oudard
21:09
Mário Fontes-Sousa

Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…

20:23
Aly-Khan A. Lalani

Choosing Wisely: 1L Combination Treatment for Advanced RCC

06:50
ecancer

ESMO 2022 Updates in Renal Cancer

Feat. T. Choueiri
19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

10:55
Yale Cancer Center

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Feat. D. Braun
14:14
PrecisCa

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

Feat. M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel